Gilead Could Goose Biotech ETFs
February 04, 2015 at 07:30 AM EST
Some well-known biotechnology exchange traded funds could be stirred by Gilead Sciences (NasdaqGS: GILD) fourth-quarter earnings report released Tuesday after the close of U.S. markets. The California-based company posted net income of $3.49 billion, or $2.18 a share, compared with $791 million, or...
